Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Biomarkers of Resiliency In Childhood Cancer Surgery

for
Pediatric Cancer, Neuroblastoma, Sarcoma,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 3 - 25

Code: NCT06674811

Recruiting

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis

for
Breast Carcinoma
Location: Newport Beach CA, Los Angeles CA
Sponsor: University of Southern California

Sex: Female

Age: 18+

Code: NCT06336928

Recruiting

Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

for
Malignant Neoplasm
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT02280161

Recruiting

Photoacoustic Imaging for Characterizing Breast Masses and Breast Tumor Response to Neoadjuvant Chemotherapy

for
Breast Cancer
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre

Sex: All

Age: 0+

Code: NCT04428528

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

for
Oncology, MEK Mutation, RAF Gene Mutation,
Location: New York NY, Fairfax VA, Buffalo NY, Pittsburgh PA,
Sponsor: Nested Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT06326411

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up

for
Cancer
Location: Jacksonville FL, Franklin TN, Irving TX
Sponsor: Center for Biomedical Research, LLC

Sex: All

Age: 0+

Code: NCT02070328

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for
Breast Cancer
Location: Moncton, Shirley NY, The Bronx NY, New York NY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06790693

Phase 3, Recruiting

A Multi Center Study of Sexual Toxicities After Radiotherapy

for
Malignant Neoplasms
Location: New York NY, Atlanta GA, Houston TX
Sponsor: Icahn School of Medicine at Mount Sinai

Sex: Female

Age: 18+

Code: NCT05394428

Recruiting

Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies

for
Cancer
Location: Washington DC, Louisville KY, Houston TX,
Sponsor: Advanced Cancer Therapeutics

Sex: All

Age: 18+

Code: NCT02044861

Phase 1, Recruiting

Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS)

for
Breast Cancer
Location: Montreal
Sponsor: Maisonneuve-Rosemont Hospital

Sex: Female

Age: 50+

Code: NCT05217966

Recruiting

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma

for
Solid Tumor, Soft Tissue Sarcoma, Metastatic Sarcoma, Sarcoma
Location: Durham NC, Chapel Hill NC, Santa Monica CA
Sponsor: NanoCarrier Co., Ltd.

Sex: All

Age: 18 - 70+

Code: NCT03168061

Phase 1, Phase 2, Recruiting

Abatacept in Immune Checkpoint Inhibitor Myocarditis

for
Myocarditis Acute, Cancer
Location: Portland ME, Boston MA, New York NY, New Brunswick NJ,
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT05335928

Phase 3, Recruiting

Study of Aerobic Training for People Receiving Treatment for Breast Cancer

for
Breast Cancer, Breast Carcinoma
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: Female

Age: 18+

Code: NCT05716893

Phase 2, Recruiting

Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer

for
Breast Cancer
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre

Sex: Female

Age: 18+

Code: NCT04050228

Recruiting

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for
Cardiotoxicity, HER2/Neu Positive,
Location: Winchester MA, Burlington MA, White Plains NY, Nyack NY,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT03418961

Phase 3, Recruiting

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

for
Metastatic Solid Tumor, Brain Metastases
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05673928

Phase 2, Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

for
MTAP-deleted Solid Tumors
Location: Boston MA, New York NY, Orlando FL, Grand Rapids MI,
Sponsor: Bayer

Sex: All

Age: 18+

Code: NCT06914128

Phase 1, Phase 2, Recruiting

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

for
Advanced Solid Malignancies
Location: New Brunswick NJ, Richmond VA, Sarasota FL,
Sponsor: Georgiamune Inc

Sex: All

Age: 18+

Code: NCT06028074

Phase 1, Phase 2, Recruiting

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

for
Solid Tumor, Sarcoma, Leiomyosarcoma,
Location: Boston MA, Lake Success NY, Fairfax VA, Cleveland OH,
Sponsor: STORM Therapeutics LTD

Sex: All

Age: 18+

Code: NCT06975293

Phase 1, Phase 2, Recruiting

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

for
Breast Cancer
Location: Lebanon NH
Sponsor: Dartmouth-Hitchcock Medical Center

Sex: All

Age: 18+

Code: NCT06258993

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial